MedTrace Logo

Hepatic Arterial Infusion Chemotherapy(HAIC) for Hepatoma After Resection

NCT02767375 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2017-08-10

No results posted yet for this study

Summary

To study if the addition of HAIC following complete removal of early stage liver cancer of HCC will prevent or delay the recurrence of the disease. Half of the participant will receive two cycles of the HAIC after the hepatectomy, while the other half will return to the baseline surveillance schedule.

Conditions

Interventions

DRUG

Oxaliplatin(OXA), 5-fluorouracil (5-FU)

for the HAIC treatment group OXA 85mg/m2, d1，0-4h 5-FU 1500mg/m2 d1, 4-24h 24 hours in d1 \& 2 , IA，q4-6 Weeks

PROCEDURE

Hepatic arterial catheter implantation

for the the HAIC treatment group: Hepatic arterial catheter implantation for HAIC

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    lead OTHER

Principal Investigators

  • Baocai Xing, Doctor · 1st Department of HBP Surgery.Beijing Cancer Hospital

  • Xu Zhu, Doctor · Interventional therapy department of Beijing Cancer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2017-12-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02767375 on ClinicalTrials.gov